Northwest Biotherapeutics develops DCVax® personalized immune therapies for solid tumor cancers. News about NWBO centers on its dendritic cell-based cancer vaccine platform, including DCVax-L for glioblastoma and DCVax-Direct for inoperable solid tumors, along with scientific presentations on next-generation dendritic cell treatments.
Company updates also cover manufacturing and treatment-logistics capacity for cell therapies, including the Sawston, UK facility, leukapheresis services, and the completed acquisition of Advent BioServices as a wholly owned subsidiary. Other recurring developments include clinical and regulatory communications, financing arrangements, capital-structure matters, operating results, and governance changes.
Northwest Biotherapeutics (NWBO) announced the acquisition of Flaskworks for approximately $4.33 million on August 28, 2020. This acquisition is expected to enhance the manufacturing process of DCVax® therapies by automating production, reducing costs, and increasing output. The Flaskworks system will transition from manual artisan methods to an assembly line approach, addressing major challenges of high costs and limited production capacity. The acquisition includes intellectual property and will streamline operations at NW Bio's facility in Sawston, UK.
Northwest Biotherapeutics (OTCQB: NWBO) announced its acquisition of Flaskworks on August 28, 2020, for approximately $4.33 million. This acquisition aims to enhance the manufacturing of DCVax® personalized immune therapies by automating the production process, which will significantly scale-up volumes and reduce costs. The Flaskworks system transforms current 'open' manufacturing processes to 'closed', minimizing the need for expensive clean rooms. The integration of Flaskworks' technology is expected to streamline operations at the Sawston, UK facility while continuing the current DCVax production methods.
Northwest Biotherapeutics (OTCQB: NWBO) is intensifying its manufacturing preparations as it nears top line data from its Phase III trial for DCVax®-L. The Company expects the Phase I buildout of its Sawston, UK facility to complete by mid-October 2020. This effort is supported by recent financings and a £1.35 million loan from the UK government. The total project cost is approximately £3.5 million (~$4.6 million). Northwest Biotherapeutics is focused on developing personalized immune therapies for solid tumor cancers, including glioblastoma.
Northwest Biotherapeutics (OTCQB: NWBO) completed a non-dilutive debt financing, securing net proceeds of $5 million. This funding aims to expand production capacity and support activities leading to the Phase III trial data readout for DCVax®-L, targeting Glioblastoma. The 21-month loan, initiated on August 17, 2020, totals $5,505,000 at an 8% interest rate, with no initial payments required for the first 7 months. The company focuses on developing personalized cancer immunotherapies and has ongoing trials for various solid tumors.
Northwest Biotherapeutics (OTCQB: NWBO) has completed outstanding clinical trial data for its Phase 3 trial of DCVax®-L for Glioblastoma brain cancer. The data includes genomic profiling for IDH mutations and imaging, which is now being integrated into the trial database. Following Data Lock, independent statisticians will access the unblinded dataset to analyze and report results. Topline data is anticipated in September 2020, with updates as the process progresses. The trial involves 331 patients and aims to provide a personalized treatment for this aggressive cancer.
Northwest Biotherapeutics (NWBO) announced a successful financing round totaling approximately $8 million on favorable terms. This includes $7 million from a stock offering priced at 32 cents per share, along with $1 million from a convertible note. Both financing components aim to strengthen the company's momentum and provide a buffer against economic uncertainties. The financing also includes suspensions on existing warrants until December 15, 2020. As the company approaches a critical Phase III trial for DCVax®-L in Glioblastoma, these funds will support necessary preparations.
Northwest Biotherapeutics (OTCQB: NWBO) announced the completion of data collection from all clinical trial sites for its Phase 3 trial of DCVax®-L, a treatment for Glioblastoma. Each site has finalized data lock, indicating significant progress despite COVID-19 challenges. The company expects remaining analyses from specialized providers to conclude in weeks, aiming to report trial results after Labor Day in September. This trial involves 331 patients and addresses one of the most aggressive forms of brain cancer. The company continues to focus on personalized cancer therapies without the toxicities of traditional methods.